Moderna Inc (MRNA) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
Total Assets Chart for Moderna Inc
Moderna Inc (MRNA) total assets for FY2025 were USD 12.3B, a -12.8% change from FY2024. Moderna Inc's total assets grew from USD 9.2M in 2014 to USD 12.3B in 2025 (133775.9% over 11 years). Total assets compound annual growth rate: 5-year CAGR of 11.0%, 10-year CAGR of 193.3%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $21.50B
- Implied Share Price
- $53.86
- Enterprise Value
- $17.90B
- Revenue (TTM)
- $2.23B
- EBITDA
- -$2.20B
- Profit Margin
- -141.43%
- Trailing P/E
- —
- Forward P/E
- 23.04
- Price/Book (MRQ)
- 3.22
- Price/Sales (TTM)
- 9.65
- EV/EBITDA
- 4.64
- EV/Revenue
- 8.10
- Dividend Yield
- —
- Book Value
- $18.66
- Free Cash Flow (FY2025)
- -$2.06B
- Free Cash Flow Yield
- -9.60%
Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.